BRCA1 and neoplasm: Importantly, at concentrations that elicited cell inhibition in BRCA1 or BRCA2 mutant cells, ART558 had minimal effects in non-tumour epithelial cells such as the human mammary epithelial cell lines, MCF10A, MCF12A and HMLE3, or in BRCA-gene wild type CAL51 triple-negative breast tumour cells (Fig. 3c).